1. Home
  2. News Archive

More News

Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements

Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...

Warburg Pincus Buys Controlling Stake in India’s Appasamy
Warburg Pincus Buys Controlling Stake in India’s Appasamy

US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...

ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front

ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...

Study Attempts to Clarify Best Fit for Vyzulta
Study Attempts to Clarify Best Fit for Vyzulta

Constance Okeke, MD, is helping to clear the confusion that can come from having multiple choices. “There are so many medicines coming into glaucoma that it can be difficult for a clinician to know...

US FDA Backs Call to Eliminate Interchangeability Designation for Biosimilars
US FDA Backs Call to Eliminate Interchangeability Designation for Biosimilars

A US FDA official has expressed support for measures before Congress to remove the interchangeability designation for biosimilars, claiming that the two-tier system is only causing confusion. It ca...

ASCRS Marks 50 Years with Look Back at Cataract Surgery in 1974
ASCRS Marks 50 Years with Look Back at Cataract Surgery in 1974

The ASCRS commemorated its 50th anniversary at its 2024 annual meeting by re-creating an ophthalmologist’s office and surgery suite from the 1970s in the exhibit hall. The display served as a remin...

J&J Vision Launches Tecnis Odyssey PC-IOL at 2024 ASCRS Meeting
J&J Vision Launches Tecnis Odyssey PC-IOL at 2024 ASCRS Meeting

Johnson & Johnson Vision launched and touted the Tecnis Odyssey presbyopia-correcting IOL at a number of venues at the 2024 ASCRS meeting. Blake Williamson, MD, and Priya Matthews, MD, described J&...

RxSight Launches the LAL+ IOL with Large ASCRS Program
RxSight Launches the LAL+ IOL with Large ASCRS Program

RxSight continued to build momentum for its post-op adjustable IOL with a big presence at the 2024 ASCRS meeting, including an Eyecelerator presentation on the new LAL+ and 14 speaker sessions at t...

Rayner and Carl Zeiss Meditec Display Recently Acquired Phaco Machines
Rayner and Carl Zeiss Meditec Display Recently Acquired Phaco Machines

The US ultrasonic cataract machine market has been dominated by Alcon, Bausch + Lomb, and Johnson & Johnson for more than a decade, so it’s unusual to learn of a new phaco machine being launched by...

Slade’s Steinert Lecture Bolsters Value of Refractive Lens Exchange
Slade’s Steinert Lecture Bolsters Value of Refractive Lens Exchange

Stephen Slade, MD, promoted the value of refractive lens exchange (RLE) during the Steinert Lecture at the 2024 ASCRS meeting’s Refractive Subspecialty Day. RLE is an elective procedure that remove...

ASCRS Meeting Showcases New Lenticule Extraction Platforms
ASCRS Meeting Showcases New Lenticule Extraction Platforms

Lenticule extraction (LE) continues to advance as new platforms come to the market. The 2024 ASCRS meeting showcased improved LE features that have enhanced the patient and surgeon experience. Doct...

Rise of DMEK Highlights Need for Corneal Endothelial Therapies
Rise of DMEK Highlights Need for Corneal Endothelial Therapies

Descemet’s membrane endothelial keratoplasty (DMEK) has become the most common keratoplasty procedure performed domestically, according to a statistical report by the Eye Bank Association of Americ...

Dry Eye Screening Before Surgery Seems Logical, but Hurdles Remain
Dry Eye Screening Before Surgery Seems Logical, but Hurdles Remain

The need to continue lobbying for dry eye evaluation prior to patients undergoing anterior segment surgery is somewhat baffling. Such testing seems like an obvious approach for the many patients wh...

Digital Solutions are Underlying Theme at 2024 ASCRS Meeting
Digital Solutions are Underlying Theme at 2024 ASCRS Meeting

The ASCRS conference was a hub of diagnostic innovation and collaboration, despite the absence of a designated “Digital Day,” as provided at the 2023 meeting. Discussions on the integration of digi...

Ophthalmologists Aim to Uncover and Overcome Gender Bias
Ophthalmologists Aim to Uncover and Overcome Gender Bias

Opinion leaders in ophthalmology collaborated to educate their peers on gender bias during the 2024 ASCRS meeting in Boston. Led by Tanya Trinh, FRANZCO, MBBS, doctors discussed detailed actions th...

Eyecelerator Celebrates Fourth Anniversary While Showcasing Innovation in Ophthalmology
Eyecelerator Celebrates Fourth Anniversary While Showcasing Innovation in Ophthalmology

A nor’easter storm that disrupted many travel itineraries failed to deter the nearly 600 industry personnel and clinicians who attended Eyecelerator ahead of the 2024 ASCRS meeting. This year’s con...

Chambers Retires from US FDA After 36-Plus Years of Ophthalmic Drug Review
Chambers Retires from US FDA After 36-Plus Years of Ophthalmic Drug Review

Wiley Chambers, MD, an ophthalmologist who conducted or supervised the review of ophthalmic drugs at the US FDA for 36½ years, retired from the agency Jan. 13, 2024. The 65-year-old is now serving ...

BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan
BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan

BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...

Emerging Companies Pursuing Ophthalmic Indications, April 2024
Emerging Companies Pursuing Ophthalmic Indications, April 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Generic Drugmakers Sued by Large Employers in Price Fixing Scheme
Generic Drugmakers Sued by Large Employers in Price Fixing Scheme

Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...

US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea
US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea

The US Justice Department has accused New York-based Regeneron of fraudulently manipulating Medicare’s drug pricing process for Eylea, costing the Medicare system hundreds of millions of dollars. T...

Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

Clinical Trial Updates for Ophthalmic Candidates , April 2024
Clinical Trial Updates for Ophthalmic Candidates , April 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Weekly Surgeon Poll, April 2024
Weekly Surgeon Poll, April 2024

Nanoscope Reports Positive Results for RP Optogenetic Therapy
Nanoscope Reports Positive Results for RP Optogenetic Therapy

Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monother-apy to restore vision i...

April 2024 Ophthalmic News Briefs
April 2024 Ophthalmic News Briefs

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...

BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan
BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan

BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...

J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million
J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million

J&J Vision’s Q1-2024 global surgical revenue totaled $348 million, up 0.3 percent (+1.1 percent cc) over $347 million in Q1-2023, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Ap...

SalioGen Selects Gene Therapy Candidate to Develop for Stargardt
SalioGen Selects Gene Therapy Candidate to Develop for Stargardt

SalioGen Therapeutics announced April 17 that it had chosen a development candidate, SGT-1001, for the treatment of Stargardt disease. SGT-1001 is being developed as a one-time, non-viral gene ther...

US FDA Backs Call to Eliminate Interchangeability Designation for Biosimilars
US FDA Backs Call to Eliminate Interchangeability Designation for Biosimilars

A US FDA official has expressed support for measures before Congress to remove the interchangeability designation for biosimilars, claiming that the two-tier system is only causing confusion. Under...

Japanese IOL Maker Hoya Halts Production After Cyberattack
Japanese IOL Maker Hoya Halts Production After Cyberattack

Japanese intraocular lens maker Hoya reported on April 4 that production of several of its products had stopped after a computer system failure, “most likely caused by unauthorized access” to its s...

Pravin Dugel, MD, Becomes President, CEO of Ocular Therapeutix
Pravin Dugel, MD, Becomes President, CEO of Ocular Therapeutix

Ocular Therapeutix announced April 15 that its executive chairman, Pravin Dugel, MD, would assume the roles of president and chief executive officer, and that Antony Mattessich is stepping down, ef...

Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme
Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme

Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...

US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea
US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea

The US Justice Department has accused New York-based Regeneron of fraudulently manipulating Medicare’s drug pricing process for Eylea, costing the Medicare system hundreds of millions of dollars. T...

US Private Equity Firm Warburg Pincus Buys Controlling Stake in India’s Appasamy
US Private Equity Firm Warburg Pincus Buys Controlling Stake in India’s Appasamy

US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...

Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis

Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...

US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate

Ocugen announced April 8 that the US FDA had cleared the company’s investigational new drug (IND) amendment to initiate a Phase III clinical trial of OCU400, a modifier gene therapy candidate for r...

Rayner Marks Sale of 5 Millionth RayOne IOL
Rayner Marks Sale of 5 Millionth RayOne IOL

UK-based Rayner reported April 3 that it had sold its 5 millionth RayOne lens and 11 millionth lens made from RayAcryl, Rayner’s proprietary hydrophilic acrylic material. Rayner, founded in 1910, r...

Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024

Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative-free, single-use, once-daily ey...

Viatris, Ocuphire Announce US Launch of Ryzumvi Eye Drops to Reverse Pupil Dilation
Viatris, Ocuphire Announce US Launch of Ryzumvi Eye Drops to Reverse Pupil Dilation

Viatris and Ocuphire Pharma announced April 1 the US launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the reversal of pharmacologically induced mydriasis. The US FDA approved Ryzumvi ...

Aldeyra Outlines New Reproxalap Trial, Aims to Resubmit NDA in Dry Eye
Aldeyra Outlines New Reproxalap Trial, Aims to Resubmit NDA in Dry Eye

Aldeyra Therapeutics on March 28 outlined its new clinical development plan for reproxalap eye drops, with the goal of resubmitting its new drug application (NDA) to the US FDA. The company said it...

Glaukos’ iDose Gets J-Code for Medical Billing in the US
Glaukos’ iDose Gets J-Code for Medical Billing in the US

The Centers for Medicare and Medicaid Services (CMS) has issued a J-code for Glaukos’ iDose. The billing code takes effect July 1, 2024. iDose TR gained US FDA approval under the 505(b)(2) pathway ...

Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts
Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts

West Point Optical Group, which operates 86 Pearle Vision clinics in 13 states, announced April 3 that it had reached an agreement with Verséa Ophthalmics to offer Verséa’s Biovance and Biovance 3L...

Beyeonics Vision Appoints A. Burton Tripathi, PhD, as CEO
Beyeonics Vision Appoints A. Burton Tripathi, PhD, as CEO

Israel’s Beyeonics Vision announced March 28 that it had appointed A. Burton Tripathi, PhD, as its new chief executive officer. Tripathi was formerly CEO of TrueVision 3D Surgical. After Alcon acqu...

Nicox Appoints Gavin Spencer, PhD, as Chief Executive Officer
Nicox Appoints Gavin Spencer, PhD, as Chief Executive Officer

France’s Nicox announced that it had appointed Gavin Spencer, PhD, as chief executive officer, effective Feb. 28. Spencer was most recently executive vice president, chief business officer, and hea...

2023 Ophthalmic Revenue Roundup for Iridex and NovaBay
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay

Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...

Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024
Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024

Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in...

State Department Offers up to $10 Million for Info on Hackers of Change Healthcare
State Department Offers up to $10 Million for Info on Hackers of Change Healthcare

The US State Department announced March 27 that it was offering a reward of up to $10 million for information on ALPHV BlackCat-linked hackers targeting critical infrastructure in the US. The agenc...

Chambers Retires from US FDA After 36-Plus Years of Ophthalmic Drug Review
Chambers Retires from US FDA After 36-Plus Years of Ophthalmic Drug Review

Wiley Chambers, MD, an ophthalmologist who conducted or supervised the review of ophthalmic drugs at the US FDA for 36 1/2 years, retired from the agency Jan. 13, 2024. The 65-year-old is now servi...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more